Skip to main content

and
  1. Article

    Open Access

    OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients

    Nowadays, evaluation of the efficacy and the duration of treatment, in context of monitoring patients with solid tumors, is based on the RECIST methodology. With these criteria, resistance and/or insensitivity...

    Sébastien Vachenc, Jessica Gobbo, Sarah El Moujarrebe, Isabelle Desmoulins in BMC Cancer (2022)

  2. Article

    Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort

    Docetaxel–cisplatin-5-FU chemotherapy is superior to 5-FU-cisplatin in terms of response rate and survival in advanced gastric cancer (AGC), but is more toxic. Oxaliplatin is better tolerated than cisplatin, w...

    Simon Pernot, Emmanuel Mitry, Emmanuelle Samalin, Laetitia Dahan in Gastric Cancer (2014)

  3. No Access

    Book

  4. No Access

    Chapter

    Traitement des cancers digestifs du sujet âgé

    Les cancers digestifs surviennent dans la grande majorité des cas chez les patients âgés de plus de 65 ans. Compte tenu du vieillissement de la population, l’incidence des cancers digestifs chez les sujets âgé...

    Emmanuel Mitry, Thomas Aparicio, Philippe Rougier in Les cancers digestifs du sujet âgé (2010)

  5. Article

    Open Access

    Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study

    The anti-VEGF antibody bevacizumab associated with an irinotecan or oxaliplatin-based chemotherapy was proved to be superior to the chemotherapy alone in first or second line treatment of metastatic colorectal...

    Astrid Lièvre, Emmanuelle Samalin, Emmanuel Mitry, Eric Assenat in BMC Cancer (2009)

  6. No Access

    Chapter

    Traitement des cancers digestifs du sujet âgé

    Les cancers digestifs surviennent dans la grande majorité des cas chez les patients âgés de plus de 65 ans. Compte tenu du vieillissement de la population, l’incidence des cancers digestifs chez les sujets âgé...

    Emmanuel Mitry, Thomas Aparicio, Philippe Rougier in Cancer du sujet âgé (2007)

  7. No Access

    Book

    Les cancers digestifs

    Avec la collaboration de l’Association des Gastro-entérologues Oncologues (AGEO)

    Philippe Rougier, Emmanuel Mitry in Oncologie Pratique (2006)